播放中国国产国语纯一级黄片免费看, 大鸡吧快来啊阿啊阿啊黄片在线播放, 中文精品日韩网站在线观看视频免费, 别揉我奶头~嗯~啊~一区二区三区,AV无码播放一级毛片免费古装,亚洲春色一区二区三区,91大神极品,美国一级大黄一片免费下载,午夜爽爽爽男女免费观看软件

Welcome to LookChem.com Sign In|Join Free

CAS

  • or
Venlafaxine, also known as Effexor, is a tertiary amino compound that is N,N-dimethylethanamine substituted at position 1 by a 1-hydroxycyclohexyl and 4-methoxyphenyl group. It is a white solid and an optically active version of a selective serotonin noradrenaline reuptake inhibitor (SNRI). Venlafaxine is an effective antidepressant, working by inhibiting the reuptake of serotonin and noradrenaline in the brain, thereby increasing their levels and improving mood.

93413-69-5

Post Buying Request

93413-69-5 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

93413-69-5 Usage

Uses

Used in Pharmaceutical Industry:
Venlafaxine is used as an antidepressant for the treatment of major depressive disorder, generalized anxiety disorder, social anxiety disorder, and panic disorder. It functions as a serotonin-norepinephrine reuptake inhibitor, enhancing the levels of serotonin and noradrenaline in the brain to alleviate symptoms of depression and anxiety.
As a selective serotonin noradrenaline reuptake inhibitor, Venlafaxine is particularly effective in addressing the imbalance of neurotransmitters that contribute to depressive and anxiety disorders. Its use in the pharmaceutical industry has provided a valuable treatment option for individuals suffering from these conditions.

Synthesis

To a suspension of Mg (0.114 g, 4.75 mmol) in THF (2 ml) a solution of dibromopentane 66 (0.536 g, 2.33 mmol) in THF (2 ml) was added drop-wise at 0-5 oC. After addition, the reaction mixture was allowed to warm to room temperature and stirred for 1.5 hours. Again, the reaction mixture was cooled to 0-5 oC and a solution of amino ester 39 (0.45 g, 1.79 mmol) in THF (5 ml) was added to it drop-wise. After the addition, the reaction mixture was first allowed to come to room temperature within 0.5 hour and then refluxed for 3.5 hours. The reaction mixture was allowed to cool and 50% aq. NaOH solution was added to the reaction mixture (pH = 12), extracted with ethyl acetate (50 ml x 2), washed with water, brine, dried over anhydrous Na2SO4, filtered and concentrated in vacuo. The residue was purified by flash column chromatography (5% MeOH in CHCl3) to furnish venlafaxine 14 as a colourless solid (0.25 g).

Biological Functions

Venlafaxine (Effexor) inhibits the reuptake of both serotonin and norepinephrine at their respective presynaptic sites.This drug does not have significant effects at muscarinic, histamine, or α-adrenergic receptors and therefore is devoid of many of the side effects associated with the TCAs.Venlafaxine and its active metabolite O-desmethyl-venlafaxine, have half lives of 5 and 11 hours respectively, so dosing twice a day is necessary. However, an extended release preparation (Effexor XR) now allows for once-daily dosing and better tolerance. Venlafaxine has a side effect profile similar to that of the SSRIs. Higher doses of venlafaxine result in modest increases in blood pressure in approximately 5% of patients.Venlafaxine has minimal effects on the cytochrome P450 enzyme system.

Pharmaceutical Applications

Venlafaxine is a serotonin and noradrenalin reuptake inhibitor (SNRI) and is used as an antidepressant. Compared to tricyclic antidepressants, it lacks the antimuscarinic and sedative side effects. Nevertheless, treatment with venlafaxine can lead to a higher risk of withdrawal symptoms.

Mechanism of action

Venlafaxine and its active metabolite, O-desmethylvenlafaxine (ODV), have dual mechanisms of action, with preferential affinity for 5-HT reuptake and weak inhibition of NE and dopamine reuptake. Venlafaxine is approximately 30 times more potent as an inhibitor of SERT than of NET. Because of the 30 times difference in transporter affinities, increasing the dose of venlafaxine from 75 to 375 mg/day can sequentially inhibit SERT and NERT . Thus, venlafaxine displays an ascending dose-dependent antidepressant response in contrast to the flat dose–antidepressant response curve observed with the SSRIs. This sequential action for venlafaxine also is consistent with its dose-dependent adverse-effect profile. Its mechanism of action is similar to imipramine. Venlafaxine is rapidly and well absorbed, but with a bioavailability of 45%, which has been attributed to first-pass metabolism. Food delays its absorption but does not impair the extent of absorption. Venlafaxine is distributed into breast milk. Venlafaxine is primarily metabolized in the liver by CYP2D6 to its primary metabolite, ODV, which is approximately equivalent in pharmacological activity and potency to venlafaxine. In vitro studies indicate that CYP3A4 also is involved in the metabolism of venlafaxine to its minor and less active metabolite, N-desmethylvenlafaxine. Protein binding for venlafaxine and ODV is low and is not a problem for drug interactions. In patients with hepatic impairment, elimination half-lives were increased by approximately 30% for venlafaxine and approximately 60% for ODV. In patients with renal function impairment, elimination half-lives were increased by approximately 40 to 50% for venlafaxine and for ODV. At steady-state doses, venlafaxine and ODV exhibit dose-proportional linear pharmacokinetics over the dose range of 75 to 450 mg/day. Steady-state concentrations of venlafaxine and ODV are attained within 3 days with regular oral dosing. Venlafaxine and its metabolites are excreted primarily in the urine (87%).

Clinical Use

Venlafaxine is a methoxyphenylethylamine antidepressant that resembles an open TCA with one of the aromatic rings replaced by a cyclohexanol ring and a dimethylaminomethyl group rather than a dimethylaminopropyl chain.

Side effects

The potential for cardiotoxicity with venlafaxine during normal use and for various toxicities in overdose situations are key concerns. Venlafaxine displays minimal in vitro affinity for the other neural neurotransmitter receptors and, thus, a low probability for adverse effects. To minimize GI upset (e.g., nausea), venlafaxine can be taken with food without affecting its GI absorption. Venlafaxine should be administered as a single daily dose with food at approximately the same time each day. The extended-release capsules should be swallowed whole with fluid and should not be divided, crushed, chewed, or placed in water. Whenever venlafaxine is being discontinued after more than 1 week of therapy, it generally is recommended that the patient be closely monitored and the dosage of the drug be tapered gradually to reduce the risk of withdrawal symptoms. Although venlafaxine is a weak inhibitor of CYP2D6, variability has been observed in the pharmacokinetic parameters of venlafaxine in patients with hepatic or renal function impairment. As a precaution, elderly patients taking venlafaxine concurrently with a drug that has a narrow therapeutic index and also is metabolized by CYP2D6 should be carefully monitored. Concurrent use of CYP3A4 inhibitors with venlafaxine has been shown to interfere with its metabolism and clearance. Similar to the other antidepressants that block 5-HT reuptake, venlafaxine may interact pharmacodynamically to cause toxic levels of 5-HT to accumulate, leading to the 5-HT syndrome.

Drug interactions

Potentially hazardous interactions with other drugs Analgesics: increased risk of bleeding with aspirin and NSAIDs; possibly increased serotonergic effects with tramadol. Anti-arrhythmics: risk of ventricular arrhythmias with amiodarone - avoid. Antibacterials: risk of ventricular arrhythmias with erythromycin, moxifloxacin - avoid. Anticoagulants: effects of warfarin possibly enhanced; possibly increased risk of bleeding with dabigatran. Antidepressants: avoid with MAOIs and moclobemide (increased risk of toxicity); possibly enhanced serotonergic effects with duloxetine, mirtazapine and St John’s wort; possible increased risk of convulsions with vortioxetine - avoid. Antimalarials: avoid concomitant use with artemether/lumefantrine and piperaquine with artenimol. Antipsychotics: increases concentration of clozapine and haloperidol. Beta-blockers: risk of ventricular arrhythmias with sotalol - avoid. Dapoxetine: possible increased risk of serotonergic effects - avoid. Dopaminergics: use entacapone with caution; increased risk of hypertension and CNS excitation with selegiline - avoid concomitant use. Methylthioninium: risk of CNS toxicity - avoid if possible.

Metabolism

Venlafaxine undergoes extensive first-pass metabolism in the liver mainly to the active metabolite O-desmethylvenlafaxine; this is mediated by the cytochrome P450 isoenzyme CYP2D6. The isoenzyme CYP3A4 is also involved in the metabolism of venlafaxine. Other metabolites include N-desmethylvenlafaxine and N,Odidesmethylvenlafaxine. Peak plasma concentrations of venlafaxine and O-desmethylvenlafaxine occur about 2 and 4 hours after a dose, respectively. The majority of venlafaxine is excreted in the urine, mainly in the form of its metabolites, either free or in conjugated form.

Check Digit Verification of cas no

The CAS Registry Mumber 93413-69-5 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 9,3,4,1 and 3 respectively; the second part has 2 digits, 6 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 93413-69:
(7*9)+(6*3)+(5*4)+(4*1)+(3*3)+(2*6)+(1*9)=135
135 % 10 = 5
So 93413-69-5 is a valid CAS Registry Number.
InChI:InChI=1/C17H28N2O/c1-18-15-9-7-14(8-10-15)16(13-19(2)3)17(20)11-5-4-6-12-17/h7-10,16,18,20H,4-6,11-13H2,1-3H3

93413-69-5SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 15, 2017

Revision Date: Aug 15, 2017

1.Identification

1.1 GHS Product identifier

Product name Venlafaxine

1.2 Other means of identification

Product number -
Other names 1-(2-(Dimethylamino)-1-(4-methoxyphenyl)ethyl)cyclohexanol

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:93413-69-5 SDS

93413-69-5Relevant articles and documents

Room-temperature Pd-catalyzed methoxycarbonylation of terminal alkynes with high branched selectivity enabled by bisphosphine-picolinamide ligand

Chen, Fen-Er,Ke, Miaolin,Liu, Ding,Ning, Yingtang,Ru, Tong

, p. 1041 - 1044 (2022/01/28)

We report the room-temperature Pd-catalyzed methoxy-carbonylation with high branched selectivity using a new class of bisphosphine-picolinamide ligands. Systematic optimization of ligand structures and reaction conditions revealed the significance of both

The total synthesis of (-) -strempeliopine: Via palladium-catalyzed decarboxylative asymmetric allylic alkylation

An, Yi,Chen, Fener,Li, Weijian,Li, Yaling,Tang, Pei,Wang, Zhenzhen,Wu, Mengjuan,Xue, Yansong

, p. 1402 - 1405 (2022/02/09)

In the work reported herein, the concise and enantioselective total synthesis of the Schizozygine alkaloid (-)-strempeliopine was developed. This synthetic strategy featured the palladium-catalyzed decarboxylative asymmetric allylic alkylation of N-benzoy

Simple RuCl3-catalyzed N-Methylation of Amines and Transfer Hydrogenation of Nitroarenes using Methanol

Sarki, Naina,Goyal, Vishakha,Tyagi, Nitin Kumar,Puttaswamy,Narani, Anand,Ray, Anjan,Natte, Kishore

, p. 1722 - 1729 (2021/04/19)

Methanol is a potential hydrogen source and C1 synthon, which finds interesting applications in both chemical synthesis and energy technologies. The effective utilization of this simple alcohol in organic synthesis is of central importance and attracts scientific interest. Herein, we report a clean and cost-competitive method with the use of methanol as both C1 synthon and H2 source for selective N-methylation of amines by employing relatively cheap RuCl3.xH2O as a ligand-free catalyst. This readily available catalyst tolerates various amines comprising electron-deficient and electron-donating groups and allows them to transform into corresponding N-methylated products in moderate to excellent yields. In addition, few marketed pharmaceutical agents (e. g., venlafaxine and imipramine) were also successfully synthesized via late-stage functionalization from readily available feedstock chemicals, highlighting synthetic value of this advanced N-methylation reaction. Using this platform, we also attempted tandem reactions with selected nitroarenes to convert them into corresponding N-methylated amines using MeOH under H2-free conditions including transfer hydrogenation of nitroarenes-to-anilines and prepared drug molecules (e. g., benzocaine and butamben) as well as key pharmaceutical intermediates. We further enable one-shot selective and green syntheses of 1-methylbenzimidazole using ortho-phenylenediamine (OPDA) and methanol as coupling partners.

Amino alcohols using the optically active amino alcohol derivative bi- Nord complex boron - -

-

Paragraph 0064; 0071-0076; 0281-0283; 0285-0286, (2021/04/16)

Disclosed are an amino alcohol-boron-binol complex as an intermediate, including Complex 3-1-1 shown below, and a method for preparing an optically active amino alcohol by using the same, wherein a racemic amino alcohol is resolved in an enationselective manner using a boron compound and a (R)- or (S)-binol, whereby an amino alcohol derivative with high optical purity can be prepared at high yield.

Method for synthesizing venlafaxine by utilizing fixed bed hydrogenation equipment

-

Paragraph 0031-0090, (2021/06/09)

The invention discloses a method for synthesizing venlafaxine by using fixed bed hydrogenation equipment, which comprises the following step: weighing methoxybenzyl cyanide and cyclohexanone as raw materials, and preparing an intermediate 1 under the action of sodium hydroxide. According to the method for synthesizing venlafaxine by using the fixed bed hydrogenation equipment, sodium hydroxide is used as alkali to produce the intermediate 1, so that ultra-low temperature and use of an active reagent are avoided, the production technical difficulty is reduced, a filled supported precious metal catalyst is adopted to carry out catalytic hydrogenation reaction, the intermediate 1 and hydrogen carry out reduction under the action of a catalyst loaded on one ore more of rhodium, palladium, and nickel, a cyan group of the intermediate 1 molecule is reduced into an amino group,venlafaxine is synthesized through fixed bed hydrogenation equipment, a supported catalyst is filled into a stainless steel reaction tube of the fixed bed hydrogenation equipment, the reactions can be carried out continuously, and the method has the characteristics of small reaction volume, large yield, safe production, and low production cost.

Bisguanidinium-Catalyzed Epoxidation of Allylic and Homoallylic Amines under Phase Transfer Conditions

Chin, Kek Foo,Kabylda, Adil M.,Lee, Richmond,Leow, Dasheng,Li, Yongxin,Tan, Choon-Hong,Xia Ang, Esther Cai,Ye, Xinyi,Zhang, Xin

, p. 2684 - 2691 (2020/03/11)

A highly enantioselective epoxidation reaction of allylic and homoallylic amines has been disclosed using an ion pair catalyst, which consists of chiral cationic bisguanidinium [BG]2+ and an achiral tetraperoxyditungstate anion [W2O2(μ-O)(O2)4]2-. The terminal oxidant is a stoichiometric amount of aqueous hydrogen peroxide, an environmentally benign reagent. Up to 96% enantiomeric excess and 99% yields were achieved for 1,1′-disubstituted and 1,2-disubstituted allylic protected amines and 1,2-disubstituted homoallylic protected amines. The identity of the ion pair catalyst was uncovered using X-ray crystallography and revealed that the achiral tetraperoxyditungstate anion species [W2O2(μ-O)(O2)4]2- is nudged nicely into the central cavity of the chiral dication. The ion pair catalyst was also characterized using infrared (IR) and Raman spectroscopies. The synthesis of (-)-venlafaxine was achieved via this reported methodology to demonstrate its usefulness.

Enantioseparation of chiral pharmaceuticals by vancomycin-bonded stationary phase and analysis of chiral recognition mechanism

Li, Jiaxi,Liu, Ruixia,Wang, Liyang,Liu, Xiaoling,Gao, Hongjie

, p. 236 - 247 (2019/02/01)

The drug chirality is attracting increasing attention because of different biological activities, metabolic pathways, and toxicities of chiral enantiomers. The chiral separation has been a great challenge. Optimized high-performance liquid chromatography (HPLC) methods based on vancomycin chiral stationary phase (CSP) were developed for the enantioseparation of propranolol, atenolol, metoprolol, venlafaxine, fluoxetine, and amlodipine. The retention and enantioseparation properties of these analytes were investigated in the variety of mobile phase additives, flow rate, and column temperature. As a result, the optimal chromatographic condition was achieved using methanol as a main mobile phase with triethylamine (TEA) and glacial acetic acid (HOAc) added as modifiers in a volume ratio of 0.01% at a flow rate of 0.3?mL/minute and at a column temperature of 5°C. The thermodynamic parameters (eg, ΔH, ΔΔH, and ΔΔS) from linear van 't Hoff plots revealed that the retention of investigated pharmaceuticals on vancomycin CSP was an exothermic process. The nonlinear behavior of lnk′ against 1/T for propranolol, atenolol, and metoprolol suggested the presence of multiple binding mechanisms for these analytes on CSP with variation of temperature. The simulated interaction processes between vancomycin and pharmaceutical enantiomers using molecular docking technique and binding energy calculations indicated that the calculated magnitudes of steady combination energy (ΔG) coincided with experimental elution order for most of these enantiomers.

Preparation method of demethylvenlafaxine succinate compound

-

Paragraph 0027; 0045; 0046; 0049, (2019/05/02)

The invention discloses a preparation method of a demethylvenlafaxine succinate compound. The preparation method is characterized in that 1-[2-amino-1-(4-methoxyphenyl)ethyl] cyclohexanol hydrochloride is taken as an initial material to prepare a demethylvenlafaxine succinate compound finished product with high purity by virtue of two-step reaction of methylation and demethylation as well as the reaction with succinic acid in a mixed solvent of acetone-water. The improved process is high in yield, low in cost, easy in operation and beneficial to the industrialized production.

A method for preparing venlafaxine hydrochloride (by machine translation)

-

Paragraph 0036; 0037; 0039; 0040; 0042; 0043, (2019/04/10)

The invention provides a preparation method of venlafaxine hydrochloride, comprises the following steps: in the borohydride and of Lewis acids in reduction system under I compound formula II compound suitcase; the formula II compound acid formation to get to the venlafaxine hydrochloride; according to the present invention provides a preparation method of venlafaxine hydrochloride, the reaction process is safe, easy to control, and the cost is low, the ideal result, is suitable for industrial production. (by machine translation)

Efficient resolution of venlafaxine and mechanism study via X-ray crystallography

Liu, Zhi-Jin,Liu, Han,Chen, Xuan-Wen,Lin, Min,Hu, Yu,Tuo, Xun,Yuan, Zhong-Yi,Sun, Xiao-Xia

, p. 268 - 274 (2018/02/19)

Numbers of resolving factors were investigated to improve resolution of venlafaxine 1. An effective resolving agent, O,O′-di-p-toluoyl-(R, R)-tartaric acid 2, was screened using similar method of ‘Dutch resolution’ from tartaric acid derivatives. The resolution efficiency was up to 88.4%, when the ratio of rac-1 and 2 was 1:0.8 in THF with little water (10:1?v/v). Enantiomerically pure venlafaxine was prepared with 99.1% ee in 82.2% yield. The chiral resolution mechanism was first explained through X-ray crystallographic study. One diastereomeric salt with well solubility forms a columnar supramolecular structure as the acidic salt (R)-1·2, while the other diastereomeric salt with less solubility forms a multilayered sandwich supramolecular structure by enantio-differentiation self-assembly as the neutral salt 2(S)-1·2. The water molecules play a key role in the optical resolution, as indicated by the special structures of the diastereomeric salts.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 93413-69-5